Loading clinical trials...

CanCan Body Composition Study | Clinical Trials | Clareo Health

RECRUITING

CanCan Body Composition Study

NCT07305753•Pennington Biomedical Research Center

Summary

The aim of this study is to develop a dataset with reference body composition measurements using criterion methods. This dataset will be used to develop new protocols to study patients with cancer. Obtaining measurements of sodium bromide (NaBr), deuterium dilution (D2O), and D3-Creatine in a stratified sample of adults will determine the accuracy (and precision) of the available devices for ECW, TBW, and skeletal muscle mass measurements.

Eligibility

Age

20 - 90 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Being either male or female
•Being an adult \>20 - \<40 or \>70 years of age.
•Having a body weight of less than 440 pounds
•Being willing to comply with the study procedures
•Not having a chronic illness (e.g., diabetes, cancer, etc.)
•Must be willing to have biospecimens and imaging stored for research use

Exclusion Criteria

•Being pregnant, attempting to become pregnant, or breastfeeding
•Having medical implants such as a pacemaker or metal joint replacements
•Having had a mastectomy, breast reduction, or breast implants
•Having hair that cannot fit in a swim cap
•Having a body weight greater than 440 pounds
•Taking medications that alter the body's fluid compartments (ex: diuretics)
•Not willing to have biospecimens and imaging stored for future research use.

Locations (1)

Pennington Biomedical Research Center

Baton Rouge, Louisiana, United States

Key Dates

Start Date

October 15, 2025

Primary Completion Date

April 15, 2026

Completion Date

May 30, 2026

Last Updated

December 26, 2025

Enrollment

ESTIMATED participants

Conditions

Healthy ParticipantsYoung Healthy AdultsElderly (People Aged 65 or More)

Contacts

Steven B Heymsfield, MD

CONTACT

2257632541 steven.heymsfield@pbrc.edu

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

NCT06342713

Healthy ParticipantsHealthy Subjects+5 more

View study

RECRUITINGPHASE1

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

NCT07310901

Obese But Otherwise Healthy Participants

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 26, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

CanCan Body Composition Study

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

Study of BW-50218 in Healthy Participants

Predictive Factors for Functional and Quality of Life Decline in Patients >65 Years With a Gastrointestinal Tract Cancer Diagnosis Taken to Curative Resectable Surgery

A Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2085

A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.